Conjugated therapeutics, including antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs), are reshaping the future of targeted therapies and driving new...
Continue Reading
Metabolic dysfunction-associated alcohol-related liver disease (MetALD) presents unique challenges for preclinical drug development, requiring models that capture the combined effects...
Continue Reading
OncoWuXi Express will continue to keep you informed of updates to our online pharmacology model database (OncoWuXi Database) and our...
Continue Reading
Substance Addiction Models and Pharmacodynamic Evaluation of Semaglutide in the Treatment of Substance Use Disorders OncoWuXi Express will continue to...
Continue Reading
Metabolic dysfunction-associated steatohepatitis (MASH) remains a significant global health challenge, driven by a complex interplay of lipid dysregulation, inflammation, and...
Continue Reading
Strategies for Novel Autoimmune Drug Development: Preclinical Efficacy and Case Studies of JAK-STAT Targeted Therapies JAK Family Molecules: Central Hubs...
Continue Reading
Building on the momentum of AACR 2026, WuXi AppTec was honored to host an outstanding group of regional industry leaders...
Continue Reading
Building on the momentum of AACR 2026, WuXi AppTec was honored to host an exceptional group of regional industry leaders...
Continue Reading
Targeting ER Mutations and Drug Resistance: R&D Strategies and Comprehensive Preclinical Evaluation of Novel ER Degraders Introduction Estrogen receptor (ER)-positive...
Continue Reading
